Advertisement

European Journal of Dermatology

, Volume 28, Issue 5, pp 713–715 | Cite as

Pneumocystis jirovecii pneumonia infection in pemphigus patients treated with rituximab: an observational nationwide epidemiological study in Taiwan

  • Kai-Che WeiEmail author
  • Wenchieh Chen
  • Pei-Ling Tang
  • Yu-Tung Huang
Article
  • 3 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cho YT, Lee FY, Chu CY, Wang LF. First–line combination therapy with Rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol 2014; 94: 472–3.CrossRefGoogle Scholar
  2. 2.
    Martin–Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with Rituximab. Chest 2013; 144: 258–65.CrossRefGoogle Scholar
  3. 3.
    Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non–HIV–infected patients: systematic review and meta–analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 1052–9.CrossRefGoogle Scholar
  4. 4.
    Su YS, Lu JJ, Perng CL, Chang FY. Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect 2008; 41: 478–82.Google Scholar
  5. 5.
    Amber KT, Lamberts A, Solimani F, et al. Determining the incidence of pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis. JAMA Dermatol 2017; 153: 1137–41.CrossRefGoogle Scholar
  6. 6.
    Wei KC, Wang YH, Wang WH, Chen W. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with Rituximab. J Eur Acad Dermatol Venereol 2017; 31: e350–1.CrossRefGoogle Scholar
  7. 7.
    Huang YH, Kuo CF, Chen YH, Yang YW. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population–based study. J Invest Dermatol 2012; 132: 92–7.CrossRefGoogle Scholar
  8. 8.
    Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti–CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51: 817–9.CrossRefGoogle Scholar
  9. 9.
    Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382–8.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Kai-Che Wei
    • 1
    Email author
  • Wenchieh Chen
    • 2
    • 3
  • Pei-Ling Tang
    • 4
  • Yu-Tung Huang
    • 5
    • 6
  1. 1.Department of DermatologyKaohsiung Veterans General HospitalKaohsiungTaiwan
  2. 2.IZZ Immunologie-Zentrum ZürichZurichSwitzerland
  3. 3.Department of Dermatology and AllergyTechnische Universität MünchenMunichGermany
  4. 4.Department of Medical Education and ResearchKaohsiung Veterans General HospitalKaohsiungTaiwan
  5. 5.Center for Big Data Analytics and StatisticsChang Gung Memorial HospitalLinkouChina
  6. 6.Department of Medical ResearchKaohsiung Medical University Chung-Ho Memorial HospitalKaohsiungTaiwan

Personalised recommendations